Theralase Technologies Inc. V.TLT

Alternate Symbol(s): V.TLT.WT | TLTFF

Healthcare Medical Devices

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.

TSXV:TLT - Post by User

Theralase Technologies Inc.

Bullboard Posts

Comment by macman1519on Mar 26, 2018 1:39pm

111 Views

Post# 27782723

RE:RE:New Paper by Dr. McFarland Provisionally Accepted Today

And minimize this!!!

LaserStock29 wrote: Sounds like a Discover and Develop JV to me on the back of phase 1b and preclin gbm and lung. Totally forgot about Osmium. How does one factor that into valuation lol. Fn joke at this level

Eoganacht wrote: A year or two ago I posted a link to an article about the different kinds of cell death induced by photodynamic therapy and their relation to anti-tumor immunity. PDT can result in apoptosis, necrosis, immunogenic cell death or autophagy. Apoptosis, which is orderly and regulated is not expected to elicit an immune response, while necrosis, the result of a trauma leading to sudden cell death is expected to be far more efficient in generating an immune response.

However, because there have been numerous reports of apoptotic cells being superior to necrotic cells in inducing anti-tumour immunity, intense research led to the new concept of immunogenic cell death or ICD. ICD is a special type of apoptosis or necrosis which is far more potent in inducing an anti-tumour immune response than non-ICD apoptosis or necrosis. The article suggests that a goal should be to develop photosensitizers which predominantly cause ICD in cancer cells.

This appears to be precisely what Dr. McFarland has done with TLD1433 and the other ruthenium and osmium based pdcs she developed.

In the article that was provisionally accepted today she explores the combatting of cancer cell resistance to the the anti-tumour immune response brought about by ICD.

Dying to be Noticed: Epigenetic Regulation of Immunogenic Cell Death for Cancer Immunotherapy

Boosting Tumor-Specific Immunity Using PDT

Epigenetic remodeling combined with photodynamic therapy elicits anticancer immune responses